Skip to NavigationSkip to content

New head for AI drug discovery firm Molplex

Published on: 07/01/16

The artificial intelligence drug discovery company Molplex has appointed Victoria Camargo as its new chief executive.

Camargo replaces the co-founder of Molplex, Dr David Leahy, and steps up after three years as the company's financial director. She brings with her invaluable experience and knowledge gained at blue chip and high-growth companies.

In 2015 Molplex signed a significant commercial deal with Astra Zeneca to develop novel cancer treatments, and it is currently engaged in a fund-raising round after securing further investment from the North West Fund for Biomedical (NWF4B).

Molplex designs novel therapeutics for various diseases using its pioneering artificial intelligence technology, allowing the development of more effective treatments faster and at a significantly lower cost.

The company is working in close partnerships with pharma companies and novel academic researchers with an aim towards discovering novel therapeutics to treat cancer and various niche but valuable disease areas.

Victoria said: "I'm extremely proud to be able to lead Molplex at such an exciting time for the company. The investment from the NWF4B will help Molplex to progress potential new drugs into efficacy trials and apply our AI technology to generate new personalised treatments for patients around the world."

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches